A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19 (BTL-TML-COVID)

B

Beech Tree Labs

Status and phase

Completed
Phase 2

Conditions

SARS-CoV-2 Infection

Treatments

Drug: BTL-TML-COVID
Drug: Placebo

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT04522830
2020-04-0311

Details and patient eligibility

About

Clinical trial to compare sublingual low does thimerosal in adults that have symptoms of SARS-CoV-2 Infection against placebo to show a difference in physical characteristics and viral levels.

Enrollment

28 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 40 years of age or older
  • Provide written informed consent
  • Have a SARS-COV-19 diagnostic test with positive results

Exclusion criteria

  • Having an oxygen saturation level below 92% at baseline or currently on Oxygen therapy
  • Subjects currently hospitalized
  • Subjects who have received a COVID vaccination
  • Subjects with a diagnosis of immunodeficiency

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

28 participants in 2 patient groups, including a placebo group

BTL-TML-COVID
Experimental group
Description:
BTL-TML-COVID
Treatment:
Drug: BTL-TML-COVID
Placebo
Placebo Comparator group
Description:
Placebo
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems